Nucleoside Analog Compounds for SARS-CoV-2 Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral treatment options for COVID-19 are limited, and existing vaccines may not be fully effective against emerging SARS-CoV-2 strains, necessitating the development of therapeutic interventions for effective treatment and prevention of coronavirus infections, particularly in vulnerable populations.
Innovation Solution
Administration of therapeutically effective amounts of specific compounds, such as RFM-011-200-5 or RFM-007-454-4, or their pharmaceutically acceptable salts, in combination with anti-infective agents like remdesivir, to treat coronavirus infections, particularly SARS-CoV-2, using a pharmaceutical composition that includes a therapeutically effective amount of these compounds and an anti-infective agent with a pharmaceutically acceptable carrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing vaccines are used against SARS-CoV-2, then vaccination can be effective against some viral infections, but long term effectiveness is uncertain and emerging strains may diminish vaccine impact
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of existing antiviral drugs to create novel compounds with improved antiviral activity. Specifically, the patent describes compounds with modified nucleoside analog structures that enhance binding affinity to viral polymerases and improve cellular uptake, thereby overcoming limitations of existing vaccines against emerging strains.
Solution Approach 2:
The patent uses intermediary compounds as mediators between the virus and the host immune system. The novel antiviral compounds described act as intermediaries that inhibit viral replication mechanisms, providing a bridge between vaccine-induced immunity and direct antiviral action, thereby enhancing overall therapeutic effectiveness.
2Reliability
If treatment options for COVID-19 are expanded, then therapeutic efficacy can be improved, but drug resistance and side effects may increase
Solution Approach 1:
The patent applies segmentation by dividing the antiviral therapy into multiple mechanism-based components. The novel compounds target specific viral enzymes (polymerases, proteases) separately from host cell processes, allowing selective inhibition of viral replication while minimizing harm to host cells. This segmented approach reduces overall drug resistance pressure compared to broad-spectrum antivirals.
Solution Approach 2:
The patent implements local quality by designing compounds with specific binding affinities for particular viral components. The novel nucleoside analogs exhibit selective binding to viral RNA-dependent polymerases rather than host DNA polymerases, creating local therapeutic effect at the viral replication site while sparing host tissues from toxicity.
3Reliability
If antiviral therapy is administered, then infection treatment can be effective, but limited treatment options reduce versatility
Solution Approach 1:
The patent applies universality by designing a platform of novel antiviral compounds that can treat multiple coronavirus strains and potentially other related viruses. The nucleoside analog framework described can be modified to target different viral polymerases, providing a universal therapeutic platform adaptable to emerging viral variants.
Data Source
AI summary
Disclosed herein ar methods that are useful for treating a subject who has a pathogenic infection, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); reducing the likelihood of the subject from being infected by a pathogen; and for reducing the transmission of a pathogen from a subject to others. The methods utilize a compound disclosed in Table 1 or Table 4 herein, optionally in combination with an additional agent such as an anti-infective agent.